RECRUITING

Cerebellar Involvement in Cognitive Sequencing

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Although there is increasing recognition that the cerebellum is involved in cognition as well as motor function, the manner in which the cerebellum contributes to cognition is uncertain. One theory that might account for both motor and cognitive contributions of the cerebellum is that the cerebellum is involved in sequencing of relevant events or stimuli. Previous experiments have suggested that disruption of the cerebellum impairs the prediction of the next event in a sequence. The present experiment will examine the impact of cerebellar stimulation on brain activation during the performance of both sequence-demanding and non-sequence-demanding tasks.

Official Title

Investigation of Cerebellar Involvement in Cognitive Sequencing

Quick Facts

Study Start:2024-03-01
Study Completion:2027-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06108336

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * 1) Age 18-50;
  2. * 2) educational attainment of at least 8 years;
  3. * 3) capable of giving informed consent;
  4. * 4) fluent speaker of English by self-report;
  5. * 5) right handed.
  1. * 1) illicit drug use within 30 days of MRI scanning;
  2. * 2) neurological or systemic disorder which can cause dementia or cognitive dysfunction;
  3. * 3) history of an Axis I psychiatric disorder including substance use disorder;
  4. * 4) history of definite stroke;
  5. * 5) focal lesion on MRI exam;
  6. * 6) uncorrected visual deficits by self-report
  7. * 7) contraindications for MRI scanning
  8. * 8) use of anxiolytic, antidepressant, neuroleptic, or sedative medication
  9. * 9) Additional exclusion criteria recommended by Wassermann for TMS neuromodulation, including: History of seizure or a family history of epilepsy, heart disease, intracardiac lines, increased intracranial pressure, history of head trauma, and history of respiratory disease

Contacts and Locations

Study Contact

John E Desmond, Ph.D.
CONTACT
410-502-3583
jdesmon2@jhmi.edu
Rida Saeed, BS
CONTACT
410-502-2150
rsaeed5@jhu.edu

Principal Investigator

John E Desmond, Ph.D.
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • John E Desmond, Ph.D., PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-01
Study Completion Date2027-07-31

Study Record Updates

Study Start Date2024-03-01
Study Completion Date2027-07-31

Terms related to this study

Keywords Provided by Researchers

  • sequencing
  • cerebellum
  • transcranial magnetic stimulation
  • TMS
  • functional MRI
  • fMRI
  • verbal working memory

Additional Relevant MeSH Terms

  • Effects of Cerebellar Stimulation on Brain Activation